FDA accepts Drug Master File, signifying a new milestone for Touchlight’s enzymatic doggybone DNA technology
Touchlight and Odimma Therapeutics announce clinical material supply agreement to develop personalised cancer therapy utilising doggybone DNA
Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform
Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform
Touchlight awarded Innovate UK grant for the measurement and intracellular visualisation of synthetic DNA constructs
Lonza and Touchlight collaborate on end-to-end mRNA offering
Touchlight awarded ILAP for therapeutic DNA vaccine
Touchlight signs patent license agreement with Pfizer for the use of dbDNA for the manufacture of mRNA-based vaccines, therapeutics and gene therapies
Touchlight and Versameb announce GMP manufacturing supply agreement
AskBio and Touchlight Restructure Joint Venture
Touchlight Ranked Number Four Fastest Growing Technology Company in the UK in the 2021 Deloitte Technology Fast 50
Touchlight to break ground on world’s highest-capacity DNA manufacturing facility
World Vaccine Congress
Join us at World Vaccine Congress, Washington DC (Apr 3-6, 2023).
Dr Lisa Caproni, Head of Vaccine Discovery, will be presenting on the topic “A rapid response platform for nucleic acid vaccines”.
Meet up with us and learn how our doggybone DNA can be used to enable faster, safer and more scalable DNA production than other traditional methods without contamination of the plasmid DNA backbone.